Citadel Advisors’s Renalytix plc American Depositary Shares RNLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-9,300
Closed -$14.9K 15484
2023
Q3
$14.9K Sell
9,300
-200
-2% -$552 ﹤0.01% 12850
2023
Q2
$27.7K Sell
9,500
-200
-2% -$453 ﹤0.01% 12433
2023
Q1
$23.5K Buy
9,700
+3,200
+49% +$8.88K ﹤0.01% 12943
2022
Q4
$12.2K Sell
6,500
-13,300
-67% -$20.8K ﹤0.01% 13523
2022
Q3
$25K Buy
19,800
+8,200
+71% +$17.9K ﹤0.01% 11989
2022
Q2
$28K Hold
11,600
﹤0.01% 12271
2022
Q1
$80K Buy
11,600
+800
+7% +$8.47K ﹤0.01% 12481
2021
Q4
$172K Buy
+10,800
New +$216K ﹤0.01% 12084
2021
Q3
Sell
-16,100
Closed -$497K 14856
2021
Q2
$497K Buy
16,100
+8,200
+104% +$245K ﹤0.01% 10079
2021
Q1
$203K Buy
+7,900
New +$198K ﹤0.01% 11671

Other funds holding RNLX

Citadel Advisors's RNLX Position: Q1 2024 in Review

Citadel Advisors sold out of Renalytix plc American Depositary Shares (RNLX) in Q1 2024, closing a stake of 104,392 shares — an estimated $40.7K sold.

Citadel Advisors first reported a position in RNLX in Q4 2020 and held it in 9 quarters. The position peaked at $1.89M in Q4 2021. 26 funds tracked by Wall St. Rank hold RNLX as of Q1 2024.

  • Citadel Advisors reported no remaining Renalytix plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 104,392 Renalytix plc American Depositary Shares shares in Q1 2024, an estimated $40.7K.
  • Citadel Advisors first reported a position in Renalytix plc American Depositary Shares in Q4 2020 and held it in 9 quarters.
  • Citadel Advisors's Renalytix plc American Depositary Shares position peaked at $1.89M in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Renalytix plc American Depositary Shares as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.